Evidence map›Paper›PMID 8885238›Full record

ArticleMolecular biology of the cell1996

Telomerase regulation during entry into the cell cycle in normal human T cells.

K J Buchkovich, C W Greider

Open access · greenAbstract read
In one paragraph

Article in Molecular biology of the cell, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 198 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Short telomere syndromes cause a primary T cell immunodeficiency.The Journal of clinical investigation · 2018
    Article
  10. Characterization in humans ofPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Article
  11. The fetal programming of telomere biology hypothesis: an update.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

K J BuchkovichCold Spring Harbor Laboratory, New York 11724, USA.
C W Greider
Cold Spring Harbor Laboratory · US

Funding

STRUCTURE/FUNCTION OF TELOMERES IN MAMMALIAN AGINGR37AG009383 · NIA · JOHNS HOPKINS UNIVERSITY · PI GREIDER, CAROL W · 1997 to 2016
$6.1M
REGULATION OF THE E2F TRANSCRIPTION FACTOR BY P300F32CA063052 · NCI · NEW YORK UNIVERSITY · PI BUCHKOVICH SASS, KAREN J · 1994 to 1994
–
STRUCTURE AND FUNCTION OF TELOMERES IN MAMMALIAN AGINGR01AG009383 · NIA · COLD SPRING HARBOR LABORATORY · PI GREIDER, CAROL W · 1991 to 1996
–
NCI NIH HHS CA-63052NIA NIH HHS AG-09383
6 · The paper itself

Abstract

Telomerase activity is involved in telomere length maintenance. Leukocytes, unlike many human somatic tissues, have detectable telomerase activity. These cells provide a normal human cell type in which to study telomerase. We studied the regulation of telomerase activity and the telomerase RNA component as leukocytes were stimulated to enter the cell cycle. In primary human leukocytes stimulated with phytohemagglutinin, telomerase activity increased > 10-fold as naturally quiescent cells entered the cell cycle. Antibodies to the T cell receptor (TCR)/CD3 complex and the costimulatory CD28 receptor induced telomerase activity in a T cell-enriched population of cells. Rapamycin, an immunosuppressant that blocks TCR/CD3 signal transduction pathways and cdk2 activation, blocked telomerase induction. Hydroxyurea, an inhibitor of S phase, did not block cdk2 kinase activity or telomerase activation. In summary, telomerase is regulated in G1 phase as normal human T cells enter the cell cycle.

Indexed as

CDC2-CDC28 KinasesCell Cycle ProteinsTumor Suppressor ProteinsAntibodiesAntigens, CD20Blotting, NorthernB-LymphocytesCD28 AntigensCD2 AntigensCell CycleCells, CulturedCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesCyclinsEnzyme InhibitorsAntibodiesAntigens, CD20CD28 AntigensCD2 AntigensCDC2-CDC28 KinasesCDK2 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesCyclinsEnzyme InhibitorsHydroxyureaImmunosuppressive AgentsInterleukin-2Microtubule-Associated ProteinsPhytohemagglutininsPolyenesProtein Serine-Threonine KinasesReceptor-CD3 Complex, Antigen, T-CellRNASirolimusTelomeraseTumor Suppressor Proteins

Identifiers

PMID8885238
PMCPMC275993
OpenAlexW1969956511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.